Type I interferon, interferon-a or -b, functions in cellular antiviral response via induction of genes called interferonstimulated genes (ISGs).
Type I interferon, interferon-a or -b, functions in cellular antiviral response via induction of genes called interferonstimulated genes (ISGs). 1) One of the most prominent ISGs is ISG15 (interferon-stimulated gene 15 kDa), which is the first identified member of the family of ubiquitin-like proteins and contains two ubiquitin-like domains. 2, 3) Recently, ISG15 was found to function as an antiviral protein against Sindbis virus, human immunodeficiency virus (HIV)-1, influenza A and B viruses, herpes simplex virus type 1, and murine g-herpesvirus. [4] [5] [6] ISG15 is conjugated to various cellular proteins (ISGylation) in a manner similar to ubiquitination that is catalyzed by the sequential action of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) 7) : the E1 (UBE1L), E2 (UbcH8 and UbcH6), and E3 enzymes (Efp and Herc5) functioning in ISGylation have been identified. 2, 3) Various target proteins modified with ISG15 have been identified, [8] [9] [10] [11] but biological consequences of ISGylation have been studied in only a few cases: for example, ISGylation of the E2 ubiquitin-conjugating enzyme Ubc13 suppresses its enzyme activity. 12, 13) Ubc13 forms a heterodimer with ubiquitin-conjugating enzyme variant 1A (Uev1A)/ methyl methanesulfonate sensitivity 2 (Mms2) and this complex is involved in formation of the Lys63 (K63)-linked polyubiquitin chain linked to the target protein. 14, 15) In addition, a functional difference between the two Ubc13 complexes has been proposed. 16) The fact that formation of the K63-linked polyubiquitin chain, catalyzed by the Ubc13-Uev1A complex, is necessary for activation of tumor necrosis factor receptor-associated factor 6 (TRAF6) and inhibitor of NF-kB (IkB)-kinase in the nuclear factor (NF)-kB pathway 17, 18) led us to speculate that ISGylation of Ubc13 affects the NF-kB pathway. In this study, to determine the effect of ISGylation on the NF-kB pathway, we examined the effect of the ISGylation system on TRAF6/transforming growth factor b-activated kinase-1 (TAK1)-dependent NF-kB activation in HEK293 cells expressing TRAF6/TAK1. We found that expression of the ISGylation system suppresses NF-kB activation via TRAF6/TAK1 and reduces the level of polyubiquitinated TRAF6. Thus, we propose that ISGylation negatively controls the NF-kB pathway.
MATERIALS AND METHODS
Cell Culture and Transfection HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Wako) supplemented with 10% heat-inactivated calf serum (Hyclone). Transfection was performed using Metafectene (Biontex) or Lipofectamine 2000 (Invitrogen).
Plasmid Construction The open reading frames of human ISG15, UBE1L, UbcH8, Ubc13, Uev1A, TAK1, and mouse TRAF6 were amplified by polymerase chain reaction (PCR). 19, 20) All constructs were verified by DNA sequencing. To generate the expression plasmids, the respective PCR fragments were subcloned into pCI-neo-6His, pCI-neoC3Flag, pCI-neo-3T7, pCI-neo-5HA, and pCI-neo-2S vectors that had been generated by inserting oligonucleotides encoding a histidine tag sequence (6His), three repeats of a Flag tag sequence, three repeats of a T7 tag sequence, five repeats of an HA tag sequence, and two repeats of an S peptide sequence, respectively, into the pCI-neo mammalian expression vector (Promega). To generate the ubiquitin expression plasmid, the pAS2-1-ubiquitin plasmid (a gift from Dr. M. Fujimuro of Hokkaido University) was digested with EcoRI and SalI and then inserted into EcoRI and SalI sites of the pCI-neo-Myc vector.
Western Blotting HEK293 cells that had been transiently transfected with the indicated plasmids and cultured for 36-48 h were lysed with lysis buffer containing 20 mM Tris-HCl, pH 7.5, 250 mM NaCl, 10 mM N-ethylmaleimide, 1 mM dithiothreitol, 1 mM sodium orthovanadate, 2 mM EDTA, 1% Triton X-100, 2 mM leupeptin and 20 mg/ml aprotinin, and the supernatant of the cell lysate was subjected to Western blotting with the indicated antibodies. To measure the level of TRAF6 polyubiquitination, the supernatant was alternatively subjected to affinity-purification with S-protein-immobilized agarose beads and the purified proteins were subjected to Western blotting with the indicated antibodies. The following antibodies were used: rabbit anti-S peptide (Santa Cruz), mouse anti-Flag tag M2 (Sigma), mouse anti-T7 tag (Novagen), mouse anti-polyubiquitin (FK2), 21) rabbit anti-ISG15, 19) mouse anti-Ubc13 (Zymed), and rabbit antiactin (Sigma) antibodies.
Reporter Gene Assay HEK293 cells were transfected with the pNF-kB-Luc reporter plasmid (BD Biosciences) and the indicated plasmids, together with pRL-TK (Promega) for normalizing transfection efficiency. Thirty-six hours after transfection, cells were lysed and luciferase activity was measured by using a Dual-Luciferase Reporter Assay System (Promega) and an AB-2000 luminescencer-PSN (Atto, Tokyo, Japan). The same experiments were repeated twice or three times.
RNA Interference Small interfering RNA (siRNA) targeting Ubc13 (5Ј-GGAAACCCAGCGUUUGCUGTT-3Ј) was purchased from Sigma. siRNA was transfected into HEK293 cells with Lipofectamine 2000 at a final concentration of 50 nM in 35 mm dishes.
RESULTS AND DISCUSSION
The NF-k kB Pathway Is Negatively Regulated by Expression of the ISGylation System We previously reported that ISGylation of the ubiquitin E2 enzymes Ubc13 12) and UbcH6 19) suppresses their ubiquitin E2 activities, suggesting that ISGylation negatively regulates the ubiquitin pathway. Ubc13 plays an important role in Toll-like receptorand interleukin-1 receptor-mediated responses. 17) To investigate the effect of ISGylation on NF-kB activation via TRAF6, the ISGylation system (ISG15, UBE1L and/or UbcH8), together with TRAF6, was expressed in HEK293 cells and an NF-kB luciferase reporter assay was carried out. We found that expression of the ISGylation system (ISG15 and UBE1L) suppresses TRAF6-dependent NF-kB activation (Fig. 1A) . Similar results were obtained in ME180 cells used for transfection (data not shown). To confirm that the suppression is associated with ISGylation, we carried out NF-kB luciferase reporter assays in the presence of various combinations of constituents of the ISGylation system (Fig.  1B) . The expression of ISG15 alone and the expression of both ISG15 and UbcH8 had little promoting rather than suppressive effects on NF-kB activation (Fig. 1B, lanes 3 and 4) . The reason for this is not clear. On the other hand, the expression of ISG15, UBE1L and UbcH8 had a suppressive effect on NF-kB activation (Fig. 1B, lane 5) , implying that the suppressive effect is dependent on the expression of UBE1L. It can be inferred that the occurrence of this situation was dependent on the endogenous amounts of the respective constituents of the ISGylation system in HEK293 cells, although the expression of all of the constituents of the ISGylation system has been reported to be induced by interferon stimulation.
2) In fact, endogenous ISG15 was found to be expressed in HEK293 cells used for transfection (data not shown). In addition, the expression of UBE1L alone had a suppressive effect on TRAF6-dependent NF-kB activation (Fig. 1C) . UBE1L is the E1 enzyme of ISGylation system and its other functions have not been reported. Therefore, it can be inferred that the suppression of NF-kB activation by UBE1L expression is based on its promotion of ISGylation. Taken together, these results suggest that ISGylation suppresses NF-kB activation via TRAF6.
Polyubiquitination of TRAF6 Is Inhibited by Expression of the ISGylation System TRAF6, a RING-domain E3, in conjunction with a heterodimeric E2 complex, Ubc13-Uev1A, promotes the formation of K63-linked polyubiquitin chains linked to TRAF6 itself in the NF-kB pathway. 17) Our finding that expression of the ISGylation system suppresses TRAF6-dependent NF-kB activation implies a suppressive effect of ISGylation on auto-ubiquitination of TRAF6. To verify this, we measured the level of TRAF6 polyubiquitination in the presence or absence of the ISGylation system. S peptide-tagged TRAF6, together with ubiquitin, ISG15 and UBE1L, was expressed in HEK293 cells. The supernatant of the cell extract was subjected to affinity-purification using Sprotein-immobilized agarose beads, and the purified TRAF6 proteins were detected by Western blotting with anti-polyubiquitin antibody FK2 (Figs. 2A, B) . It was found that the level of polyubiquitinated TRAF6 was reduced by the presence of the ISGylation system (ISG15 and UBE1L). This re- 2224 Vol. 31, No. 12
Fig. 1. NF-kB Activation via TRAF6 Is Suppressed by Expression of the ISGylation System
HEK293 cells were transiently transfected with pCI-neo-3T7-TRAF6 and the ISGylation system containing pCI-neo-3T7-ISG15 and pCI-neo-5HA-UBE1L (A), pCI-neo-2S-TRAF6, pCI-neo-3T7-ISG15, pCI-neo-5HA-UBE1L and pCI-neo-5HA-UbcH8 (B), and pCI-neo-3T7-TRAF6 and pCI-neo-5HA-UBE1L (C), together with pNF-kB reporter plasmid. The cells were then lysed, and luciferase activity was measured. Results are expressed as fold induction in luciferase activity relative to that of control mocked cells that had been transfected with an empty vector. Triple experiments were carried out, and the error bars represent the standard deviation. Asterisks show significant differences at * * pϽ0.01 and * pϽ0.05 by the t-test. sult confirms the above assumption that ISGylation suppresses NF-kB activation via TRAF6.
Ubc13 Is a Possible Target Protein for ISGylation in
the NF-k kB Pathway Since the Ubc13-Uev1A complex has been shown to be involved in K63-polyubiquitination of TRAF6, 17) we next investigated whether Ubc13 is a target protein for ISGylation in the suppressive effect of ISGylation on TRAF6-dependent NF-kB activation. When both Ubc13 and Uev1A were expressed together with TRAF6, the NF-kB activity promoted by TRAF6 was unexpectedly repressed by both Ubc13 and Uev1A, though the extent of repression was small (Fig. 3A, lanes 2 and 3) . On the other hand, irrespective of the expression of Ubc13 and Uev1A, expression of the ISGylation system (ISG15, UBE1L and UbcH8) suppressed TRAF6-dependent NF-kB activation (Fig. 3A, lanes  3, 5 and 6 ). We assumed that the amounts of endogenous Ubc13/Uev1A in HEK293 cells are sufficient for TRAF6-dependent NF-kB activation, although the reason for the suppressive effect of exogenous Ubc13/Uev1A remains unknown. Endogenous Ubc13, as well as exogenous Ubc13 tagged with a Flag tag, was detectable by Western blotting with anti-Ubc13 antibody (Fig. 3B) . To determine the involvement of Ubc13 in TRAF6-dependent NF-kB activation, we carried out a Ubc13 knockdown experiment using siRNA targeting Ubc13 (Fig. 3C) , and we found that Ubc13 knockdown reduced TRAF6-dependent NF-kB activation (Fig. 3D,  lanes 2 and 4) . Considering that in our system Ubc13 plays an important role in TRAF6-dependent NF-kB activation possibly through its involvement in TRAF6 polyubiquitination, together with the results of our previous study showing that Ubc13 is ISGylated to become inactivated, 12) we propose that ISGylation of Ubc13 results in the reduction of its E2 activity, leading to the suppression of NF-kB activation via TRAF6. It should be noted that transfection of plasmids for ISGylation system and siRNA targeting Ubc13 reduced TRAF6-dependent NF-kB activation more strongly than transfection of either of them did (Fig. 3D, lanes 3-5) . These results could be explained by either of the following possibilities, i.e., ISGylation of Ubc13 that had not been subjected to knockdown or ISGylation of other target proteins such as protein phosphatase 2Cb that negatively regulates the NF-kB pathway.
20)
NF-k kB Activation via TAK1 Is Controlled by Expression of the ISGylation System It is well known that TAK1 is a key regulator downstream of TRAF6 in the NF-kB pathway: phosphorylation by TAK1 and subsequent K63-polyubiquitination by Ubc13/Uev1A of a subunit of the IkB kinase complex are needed to activate the IkB kinase complex, which results in phosphorylation, ubiquitination and degradation of IkB, leading to the activation of NF-kB. 17, 22) We investigated the effect of ISGylation on the activation of NFkB via TRAF6 and TAK1. TAK1, together with TRAF6 and the ISGylation system (ISG15, UBE1L and UbcH8), was expressed in HEK293 cells and an NF-kB luciferase reporter assay was carried out. As expected, the expression of TAK1 had an additional stimulatory effect on NF-kB activity, promoted by TRAF6, and NF-kB activation via both TRAF6 and TAK1 was suppressed by expression of the ISGylation system to a level almost the same as that in the case of NFkB activation via TRAF6 alone (Fig. 4A ), suggesting that a common factor downstream and upstream of TAK1 is affected by expression of the ISGylation system. We next carried out NF-kB luciferase reporter assays in the presence of various combinations of constituents of the ISGylation system, and the results in the case of NF-kB activation via TRAF6 and TAK1 (Fig. 4B) were almost the same as those in the case of activation via TRAF6 alone (see Fig. 1B ): the suppressive effect is dependent on the expression of UBE1L. It should be noted again that the expression of ISG15 alone and the expression of both ISG15 and UbcH8 have substantial promoting effects on TRAF6/TAK1-dependent NF-kB activation as in the case of TRAF6-dependent NF-kB activation (see Fig. 1B ). Taken together, the results suggest that Ubc13, a common factor upstream and downstream of TAK1, is a target protein for ISGylation and that its ISGylation leads to suppression of the NF-kB pathway. Fig. 4 . NF-kB Activation via TRAF6 and TAK1 Is Suppressed by Expression of the ISGylation System HEK293 cells were transiently transfected with the indicated plasmids together with pNF-kB reporter plasmid. The cells were then lysed, and luciferase activity was measured. The ISGylation system in (A) contained pCI-neo-3T7-ISG15, pCI-neo-5HA-UBE1L and pCI-neo-5HA-UbcH8. Results in triple (A) and double (B) experiments are expressed as in Fig. 1A and asterisks show significant differences at * * pϽ0.01 and * pϽ0.05 by the t-test.
